菲茨杰拉德(Cantor Fitzgerald)将布里斯托尔-迈尔斯(Bristol-Myers Squibb)的目标价格降至55美元, Cantor Fitzgerald lowers Bristol-Myers Squibb's target price to $55, despite beating earnings expectations.

投资公司Cantor Fitzgerald对Bristol-Myers Squibb(BMY)保持“中立”评级,将股票目标价格降至55.00美元。 Investment firm Cantor Fitzgerald maintained a "neutral" rating on Bristol-Myers Squibb (BMY), lowering the stock's target price to $55.00. 布里斯托尔-迈尔斯·斯基布最近的季度收入为每股1.67美元,比分析员的预期高出0.20美元。 Bristol-Myers Squibb's recent quarter earnings of $1.67 per share exceeded analysts' expectations by $0.20. 公司股票的市场上限为99.6亿美元,商定价格目标为57.67美元。 The company's stock has a market cap of $99.60 billion and a consensus price target of $57.67. Bristol-Myers Squibb提供癌症、心脏病和免疫学等疾病的治疗。 Bristol-Myers Squibb offers treatments for diseases like cancer, heart conditions, and immunology. 该公司还宣布季度红利为0.62美元,收益率为5.07%。 The company also announced a quarterly dividend of $0.62, with a yield of 5.07%.